CAR-T Cell Product Development Guidance Covers Previous Recipients, ‘Bridging Therapy’
Executive Summary
Testing of autologous therapy in clinical trial patients who previously received CAR-T cells requires special consideration in initial material testing and study design, US FDA says in a draft guidance that also addresses potential need for bridging therapy in the event of a manufacturing delay or failure.
You may also be interested in...
Gene/Cell Therapies: Sponsors Must Plan For Long-Term Safety Follow-Up Even If They Fold
In final guidance documents on development of CAR-T cell products and human genome therapies incorporating genome editing, US FDA says that sponsors should plan for continued follow-up, with funding, even if they cease operations or withdraw the IND.
Actemra CAR-T-Related Indication Comes With Help From Novartis, Kite, US FDA
Genentech's interleukin-6 inhibitor got bonus approval based on data from development programs for Novartis' and Kite's chimeric antigen receptor T-cell therapies; CAR-T developers allowed FDA to access the Actemra-related data in their applications and conduct its own pooled analysis.
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
Risk Evaluation and Mitigation Strategy for Kymriah requires the acute lymphoblastic leukemia treatment be administered by certified centers, while a postmarketing study will assess safety over 15 years. FDA's early approval reflects efforts by the biologics center and new cross-cutting Oncology Center for Excellence to implement a more collaborative review model.